Skip to main content

Search

Reset all filters
456 Result(s)
Sort by

Interview with Michael Schmelmer

Interview with Michael Schmelmer

"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Phase 3 studies survodutide obesity and overweight

Phase 3 studies survodutide obesity and overweight

Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Growing with us

Growing with us

We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.
George Okafo

George Okafo

My career challenge at Boehringer Ingelheim by George Okafo. Read it now!
Investment of 65 million euro in avian vaccines in France

Investment of 65 million euro in avian vaccines in France

Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines
What we do

What we do

Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Questions and Answers

Questions and Answers

Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
European Election: Europe needs our vote

European Election: Europe needs our vote

This week, over 400 million citizens from the 27 European Union (EU) Member States will be able to elect a new European Parliament. Our vote can help to make a better and stronger Europe..